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| INTRODUCTION
Hepatitis C virus (HCV) genotype 3 is the second most prevalent genotype worldwide, 1 and associated with several features, such as accelerated progression of fibrosis and a greater risk of steatosis and hepatocellular carcinoma (HCC), [2] [3] [4] that significantly increase liver-related hospitalization and death relative to other genotypes. 5 Thus, there is an urgent need for safe and effective treatment of genotype 3 infection.
All-oral HCV regimens have greatly improved treatment safety and efficacy relative to treatment with pegylated interferon (pegIFN) and ribavirin (RBV). However, some current oral agents have limited activity against genotype 3. Daclatasvir (DCV), a non-structural protein 5A
(NS5A) inhibitor, and sofosbuvir (SOF), a non-structural protein 5B
(NS5B) inhibitor, are pan-genotypic oral HCV antivirals with potent activity against genotype 3. 6,7 In the phase 3 ALLY-3 study, 12 weeks of DCV+SOF treatment resulted in a 96% rate of sustained virological response at post-treatment week 12 (SVR12) in non-cirrhotic patients with genotype 3. 8 This regimen is now a recommended option for non-cirrhotic genotype 3 infection in several clinical guidelines, including the European Association for the Study of the Liver, the American
Association for the Study of Liver Diseases and the Association Française pour l'Etude du Foie guidelines.
9-11
Genotype 3 is more difficult to treat in patients with cirrhosis.
An SVR12 rate of 86% was observed among genotype 3-infected patients with compensated cirrhosis following 12 or 16 weeks of
Methods:
Patients with F3/F4 fibrosis and/or extrahepatic hepatitis C virus manifestations, post-liver transplant hepatitis C virus recurrence and/or indication for liver/ kidney transplant, were treated with daclatasvir+sofosbuvir (60+400 mg daily) for a recommended duration of 24 weeks. Addition of ribavirin and/or shorter treatment was at physician's discretion. The primary efficacy analysis was sustained virological response at post-treatment week 12 (SVR12; modified intention-to-treat). Safety was assessed by spontaneous adverse event reporting.
Results:
The efficacy population comprised 333 patients, mostly cirrhotic (77%, of whom 18% were decompensated) and treatment experienced (72% 
Conclusions:
Daclatasvir+sofosbuvir achieved high SVR12 rates and was well tolerated in this large real-world cohort of GT3-infected patients with advanced liver disease, without benefit of ribavirin in those treated 24 weeks.
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• A real-world early access programme treated HCV genotype 3-infected patients with highly advanced disease and no other treatment options with daclatasvir plus sofosbuvir. Many would have been ineligible for a randomized study.
• Sustained virological response after 24 weeks of treatment was 89%: 98% without cirrhosis; 86% with cirrhosis (including decompensated cirrhosis). There was no incremental benefit with concomitant ribavirin.
• Only 1% of patients were recorded to have discontinued for an adverse event.
• Daclatasvir and sofosbuvir, with or without ribavirin, was effective and well tolerated in this real-world cohort of HCV genotype 3-infected patients with advanced disease.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATU, Autorisation Temporaire d'Utilisation; CYP3A4, cytochrome P450 3A4; DCV, daclatasvir; gamma GT, gamma-glutamyl transferase; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITT, intention-to-treat; LLOQ, lower limit of quantification; MELD, Model for End-Stage Liver Disease; mITT, modified intention-to-treat; NS5A, non-structural protein 5A; NS5B, non-structural protein 5B; pegIFN, pegylated interferon; PT12, post-treatment week 12; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virological response at PT12; TAR, Treatment Access Request; VA, Veterans Administration.
DCV+SOF+RBV in the phase 3 ALLY-3+ study. 12 The combination of DCV+SOF for 24 weeks, with or without RBV, is a recommended option for genotype 3 infection with cirrhosis in several guidelines, [9] [10] [11] but there are few empirical data for this duration.
Early access initiatives allow access to promising new drugs ahead of their marketing authorization for patients with high unmet needs. 
| PATIENTS AND METHODS

| Patients
Patients enrolled in the ATU programme infected with HCV genotype 3
were included. Eligible patients were adults with chronic HCV infection, no alternative treatment options and an indication for treatment as a result of (i) advanced liver disease (physician-assessed F3 or F4 METAVIR or METAVIR-equivalent fibrosis and/or severe extrahepatic HCV manifestations), (ii) post-liver transplant HCV recurrence or (iii) an indication for a liver or kidney transplant.
| Determination of cirrhosis
Enrolled patients were assigned a cirrhosis status on the basis of a hierarchical algorithm (Table S1) 
| Treatment dose and duration
Recommended treatment was DCV 60 mg+SOF 400 mg, once daily, for 24 weeks. RBV could be added and/or shorter treatment undertaken at the physician's discretion. DCV 30 mg was recommended with ritonavir-boosted atazanavir or other potent inhibitors of cytochrome P450 3A4 (CYP3A4) or P-glycoprotein; and DCV 90 mg with efavirenz or other moderate inducers of CYP3A4. DCV was contraindicated with potent CYP3A4 or P-glycoprotein inducers, and not recommended in pregnancy or women of childbearing potential not using effective contraception. 
| Programme conduct
| Assessments
Hepatitis C virus-RNA was assessed by local laboratories using their own protocols. For each returned visit form, quantitative HCV-RNA data were provided along with the assay and lower limit of quantification (LLOQ) used, and an outcome of "quantifiable" (>LLOQ) or "unquantifiable" (≤LLOQ) was assigned. Where a qualitative result was reported, HCV-RNA was considered unquantifiable if target RNA was undetected.
Safety was evaluated as frequencies of serious AEs, AEs and discontinuations for AEs. The physician was responsible for AE reporting.
Standard pharmacovigilance practice was used, imputing AEs of unreported causality as treatment related.
| Analysis of populations and endpoints
The treated (safety) population comprised all patients with ≥1 postday 0 visit form or AE report; the intention-to-treat (ITT) population was the subset with detectable baseline HCV-RNA and >1 day of treatment.
The primary efficacy analysis was a modified ITT (mITT) approach which excluded ITT patients without virological data at PT12 because of discontinuation or dropout for reasons other than predefined treatment failure.
The primary efficacy outcome was SVR12, defined as unquantifiable HCV-RNA at PT12. Treatment failure was failure to achieve SVR12 for defined virological or non-virological reasons. Virological failure con- analysis was also performed which excluded non-virological failures.
| Statistical analysis
Missing PT12 data were back-imputed from the next available measurement; other intermittent missing data were imputed as the worse of the two flanking outcomes.
DCV treatment duration was derived from the documented start and end dates. Start date was taken from the listed date for DCV initiation, the pharmacovigilance database or the date of day 0. Treatment end was as listed in the treatment discontinuation form or the last DCV discontinuation date with no new dose or resumption, taken from the pharmacovigilance database or imputed from the last on-treatment visit. Primary analyses were based on actual treatment duration, analysed as 12 weeks (≤14 weeks of actual treatment) or 24 weeks (>14 weeks). Sensitivity analyses were undertaken for the duration initially considered by the physician (reported in the TAR), and for actual durations <10, 10-<14, 14-<20 and ≥20 weeks.
| RESULTS
| Patients
A total of 560 genotype 3-infected patients referred by 280 physicians were enrolled from 4 March to 27 October 2014. From these, a treated population of 516 and an mITT efficacy population of 333 patients were derived ( Figure 1A ).
Baseline characteristics (mITT population) are shown in Table 1 .
Patients were primarily treatment experienced (72%), of whom 60% had prior relapse, 21% null response and 19% partial response. Cirrhosis was present in 77% (18% of whom were decompensated), and 19% of 145 cirrhotic or pretransplant patients with data had a Model for End-Stage Liver Disease (MELD) score ≥15. Baseline albumin was <35 g/L in 27%;
baseline HCV-RNA ≥6 million IU/mL in 50%, and 14% were co-infected with human immunodeficiency virus (HIV). Baseline characteristics for the 138 ITT patients excluded from the mITT analysis were similar to the 333 mITT patients (Table S2) 
| Virological response
Overall SVR12 rates and causes of treatment failure are shown in 
| Treatment failure
There were 55 treatment failures: 45 virological (4 breakthroughs, (n=9) or treatment discontinuation for an AE (n=1; ascites/hepatocellular carcinoma/encephalopathy/pneumonia). All undefined virological failures were in patients whose last available HCV-RNA data through PT12 was a quantifiable reading at treatment week 2 or 4.
Individual characteristics of these 55 patients are shown in Table   S4 , and aggregate characteristics for virological and non-virological failures vs SVR12 successes in Table S5 . Overall, patients with treatment failure showed more advanced indicators of baseline liver disease-more decompensated cirrhosis and MELD scores ≥15, lower platelets and albumin, and higher gamma GT-than patients who achieved SVR12. This trend was particularly marked in patients with non-virological failure, of whom 70% had decompensated cirrhosis and 57% MELD ≥15, along with more laboratory abnormalities than those with virological failure or achieving SVR12.
| Liver disease measures pre-and post-treatment
Paired baseline and PT12 Child-Pugh data were available in 67
patients and MELD score in 46 patients. All patients enrolled in the ATU programme N=3876
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T A B L E 1 Baseline characteristics At PT12, Child-Pugh class improved in 69% (9/13) of patients with decompensated cirrhosis (class B to A, n=7; class C to A, n=2), remained unchanged in 15% (2/13; both class B), and worsened in 15% (2/13; both class B to C). Among 54 patients with Child-Pugh A cirrhosis, 96% (52/54) remained unchanged at PT12 and 4% (2/54) progressed to class B.
All patients (n=24) with MELD scores <10 and paired data remained <10 at PT12. Of 12 patients with MELD scores 10-<15, 58% (7/12) were <10 at PT12, and the rest unchanged. Of 10 patients with MELD scores ≥15, 50% (5/10) improved at PT12 (two dropped to <10, three to 10-<15), while the remaining 5 remained unchanged.
| Safety
On-treatment safety (treated population) is shown in Table 4 . Overall More serious AEs occurred among patients receiving RBV, but with no apparent influence of treatment duration (Table 4) . Compared with patients with available data not receiving RBV (n=395), those receiving RBV (n=109) experienced more serious gastrointestinal (10% vs 4%), hepatobiliary (5% vs 2%) and psychiatric disorders (4% vs 1%) and more neoplasms (7% vs 3%), consistent with the trend towards more advanced baseline disease observed in patients prescribed RBV. Three patients experienced a grade 3/4 reduction in haemoglobin (lowest on-treatment level 7.5-7.8 g/dL); none were receiving RBV.
Overall, the incidence of AEs in cirrhotic patients with baseline MELD data was similar between those with low (<10; n=134), intermediate (10-<15; n=56) and high (≥15; n=40) MELD scores (37%, 32%, 40% respectively). However, serious AEs were more common for scores ≥15 than <15 (30% vs 14%), particularly gastrointestinal disorders (15% vs 5%); infections/infestations, nervous system disorders and hepatobiliary disorders (each 13% vs 2%); and metabolism/nutrition disorders (8% vs 2%). Death was also more common for MELD ≥15 than <15 (10% vs 1%).
| DISCUSSION
Hepatitis C virus genotype 3 has generally proven more challenging to treat with oral antivirals than other genotypes. This large real-world cohort of patients with genotype 3 infection plus advanced liver disease provides data on the clinical effectiveness of DCV+SOF (±RBV) in a challenging subset of patients with very limited options. Among these, overall SVR12 rates of 89% without RBV and 82% with RBV were observed after 24 weeks of treatment. for 24 weeks received no SVR12 benefit over those treated without RBV (88% vs 89%). 13 Other real-world data in less clinically Although baseline measures of advanced liver disease, such as decompensated cirrhosis and high MELD scores, were associated with higher rates of treatment failure, death and serious AEs in the ATU programme, overall rates of death (2%) and discontinuations because of AEs (1%) were infrequent. Child-Pugh class and MELD score improved in the majority of decompensated or high-MELD patients for whom baseline and PT12 data were available, although the caveat applies that the number of paired measures was limited and largely restricted to patients achieving SVR12.
The ATU programme represents one of the largest observational assessments thus far of patients with HCV genotype 3 and advanced disease. However, as with all real-world data, there are limitations for interpretation. One important limitation is that drug allocation was not randomized; both treatment duration and use of RBV were entirely at the physician's discretion. This introduces a potential source of bias and an imbalance in group sizes that renders it impossible to fully assess the effect of RBV, particularly since it was more likely to have been prescribed to patients considered harder to treat. Another is that data collection and assessment were non-standardized and based on local practice, resulting in substantial intersite variability in the definitions of certain parameters and the frequency of follow-up, as well as a significant amount of missing data. A third limitation is that data were returned voluntarily; it was not possible to establish whether missing data were caused by loss to follow-up, and physicians may have provided follow-up information based on individual results, thus biasing an intention-to-treat analysis to underevaluate efficacy. Finally, collection of safety data was based on pharmacovigilance rather than continuous prospective assessment; it is therefore likely that AEs were under-reported.
Despite these limitations, observations from this cohort of patients with advanced disease-many of whom would not have been eligible for a clinical trial-are consistent with phase 3 studies of DCV+SOF±RBV, and with multinational real-world data from the European Union. All-oral treatment with DCV+SOF±RBV achieved high SVR12 rates and was well tolerated in HCV genotype 3-infected patients with advanced liver disease.
T A B L E 4 On-treatment safety summary by derived regimen (all treated patients; N=516) Neutropenia, dermatitis allergic, unreported event, ascites/HCC/encephalopathy/pneumonia, patient request/unreported AE (n=1 each). b Deep vein thrombosis/pulmonary embolism (n=1); multi-organ failure/hepatorenal syndrome (n=1); septic shock with multi-organ failure/intestinal obstruction (n=1), peritonitis (n=1) or lymphoma/chronic hepatitis C/respiratory distress (n=1); haemorrhagic stroke (n=1); renal impairment (n=1); unknown/ unreported cause (n=4).
